Contact A Lawyer
Have A Potential Case Reviewed By An Attorney
Side effects of Abilify have been linked to serious and potentially devastating risks, including impulse control problems for adults that may lead to substantial gambling losses. In addition, use of the medication among children has been linked to a potential risk of childhood diabetes from Abilify.
ABILIFY LAWSUIT STATUS: Product liability lawyers are investigation potential Abilify gambling lawsuits and Abilify childhood diabetes lawsuits for individuals throughout the United States. Cases are handled under a contingency fee agreement, which means that there are no attorney fees or expenses unless a recovery is obtained.
MANUFACTURERS: Bristol-Myers Squibb and Otsuka American Pharmaceutical Inc.
OVERVIEW: Abilify (aripiprazole) was approved by the FDA in 2002 for the treatment of a number of psychological disorders. It is now approved for use among both adults and children, and is commonly prescribed to treat schizophrenia, autism, bipolar disorder and depression.
Known as a partial dopamine receptor agonist, Abilify works in a manner different from other antipsychotics.
Amid aggressive marketing and advertisements, Abilify has grown to become one of the top-selling brand name medications in the United States, generating more than $6 billion in worldwide sales in 2013. However, it appears that inadequate and insufficient warnings were provided for users and the medical community.
ABILIFY GAMBLING LOSSES: Research has linked Abilify and other dopamine receptor agonists (which are typically used for treatment of Parkinson’s disease, restless leg syndrome and related condition) to potential impulse control problems. This may cause users to engage in compulsive gambling, and other compulsive behavior, such as sex addictions or shopping addictions.
As early as 2009, researchers warned that dopamine receptor agonists used for treatment of Parkinson’s disease may lead to compulsive disorders.
In a study published in October 2014, which further examined this risk, researchers pointed out that there are also safety signals suggesting a link between a lack of impulse control and Abilify side effects.
In May, the FDA issued a drug safety communication announcing it was requiring Abilify to carry new warnings of the risks of compulsive behavior. In addition, a study published in July found that Abilify only provided modest benefits for the treatment of depression.
As a result of the failure to warn about the potential Abilify gambling risks, patients and the medical community were deprived of the opportunity to recognize early signs and symptoms, which may have prevented the addictive gamblers from suffering substantial losses, incurring debt, destroying families, losing employment and suffering damage to their overall quality of life.
ABILIFY CHILDHOOD DIABETES SIDE EFFECTS: Weight gain is another potential risk associated with the atypical antipsychotic medication, but it appears that inadequate warnings were provided about the risk that children on Abilify may develop diabetes.
A study published in November 2011 in the medical journal Pediatrics, found that antipsychotics like Abilify may increase a child’s risk of diabetes four-fold.
A study published in October 2013 found that Abilify increased the risk of diabetes in children by a factor of seven (supplemental content, purchase required).
Diabetes is a chronic condition that can have devestating health consequences for a child over the remainder of their life. This may require adherence to a diabetes diet and various medications or insulin therapy, posing an increased risk of complications associated with diabetes, such as:
- Heart and Blood Vessel Disease
- Kidney Damage
- Nerve Damage
- Foot Injury or Amputation Risk
- Alzheimer’s Disease
- Eye Problems
- Hearing Impairment
- Skin Problems
- Sexual Dysfunction
- Pregnancy Complications
- Premature Death
FIND OUT IF YOU MAY QUALIFY FOR AN ABILIFY LAWSUIT: Lawsuits allege that Bristol-Myers Squibb and Otsuka knew or should have known about this potential Abilify side effects and failed to provide adequate warning to patients, parents or the medical community about the potential for severe impulse control disorders and childhood diabetes.